The March open-label readout on MZE829 was the first clinical proof that an oral dual-mechanism APOL1 inhibitor can lower proteinuria in a genetically defined, mixed APOL1-mediated kidney disease population. The equity treated that print as a franchise event and then spent the following months unwinding the multiple as investors digested the sample size, the absence of a placebo arm, the softer diabetic subgroup, and a more advanced competitor already running a registrational program. Maze is no longer a discovery story waiting for a first human signal. It is a two-asset kidney company whose lead program has a signal and whose share price now sits near the year low, asking whether that signal is large and clean enough to support a registrational start next year.
Management used the window after the readout to complete a registered follow-on and to keep a Hercules delayed-draw facility and a Jefferies at-the-market program in reserve. Mid-year cash, cash equivalents and marketable securities were $495 million. Management states that balance funds the current plan into 2029. That liquidity is real, and it is also why the equity can absorb a messy expansion cohort without an immediate going concern debate. The operating print underneath is less flattering. Second-quarter research and administrative spend both stepped up as HORIZON enrollment and registrational preparation replaced the cheaper mid-stage start-up year.
The next test is not another financing. It is whether larger HORIZON cohorts, due around year-end or early next year, reproduce the non-diabetic and FSGS proteinuria drops with enough patients to justify a first-half registrational start in moderate disease without diabetes. In parallel, Vertex's AMPLITUDE interim and AMPLIFY modest-proteinuria work define how much commercial room a later oral APOL1 inhibitor still has. The expansion data either confirms a dual-mechanism lane in a genetically defined population, or it leaves Maze as a well-funded second program in a race the market already assigned to someone else.